The CG-100 Intraluminal bypass device is being evaluated as a treatment to determine whether it can reduce the need for a diverting stoma and its related complications
If you are a rectal cancer patient between the ages of 22 and 70 and  need  to undergo colorectal surgery, you may qualify for our research study
A clinical study is underway across the U.S. for people undergoing colorectal surgery

See if the CG-100 procedure is right for you

Where is the CG-100 available?

  • Henry Ford Hospital- Detroit Michigan
  • Miriam Hospital- Providence Rhode Island
  • University of Louisville Hospital- Louisville Kentucky
  • University of Colorado Anschutz Medical Campus- Aurora Colorado
  • University of Utah Health- Salt Lake City Utah
  • University of California- Irvine California
  • NY Presbyterian Weill Cornell Hospital- New York New York
  • University of Minnesota Medical Center- Minneapolis Minnesota
  • Kaiser Permanente Medical Center- San Diego California
  • Jefferson Hospital- Philadelphia Pennsylvania

The CG-100 Intraluminal bypass device

A temporary protective bypass device which is being evaluated as a treatment to determine whether it can reduce the need for a diverting stoma and its related complications. The CG-100 device is designed to avoid contact of the anastomotic site with fecal material during its critical healing period. The study will evaluate whether it can reduce the life-threatening symptoms related to clinical anastomotic leaks.
Are you eligible?

The CG-100 Clinical study

The CG-100 clinical study is underway at select sites across the U.S.
Learn More

News

Clinical Trial Allows Participants to Avoid an Ileostomy During Surgery for Rectal Cancer

Jon Vogel, MD, is leading the CU Anschutz site of a nationwide study comparing the Colospan bypass device with standard of care treatment.

More News